| Excluded for Being Included in Melnikow 201841 |
|---|
| Ogilvie G, van Niekerk D, Krajden M, et al. Effect of screening with primary cervical hpv testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: The hpv focal randomized clinical trial. JAMA. 2018;320(1):43-52. |
| Ogilvie GS, Krajden M, van Niekerk D, Smith LW, Cook D, Ceballos K, et al. HPV for cervical cancer screening (HPV FOCAL): complete round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer. IJC. 2017;140(2):440-448. |
| Canfell K, Caruana M, Gebski V, Darlington-Brown J, Heley S, Brotherton J, et al. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial. PLoS Medicine. 2017;14(9):e1002388. |
| Excluded for Countries of Origin |
|---|
| Wong EL, Cheung AW, Huang F, Chor JS. Can Human Papillomavirus DNA self-sampling be an acceptable and reliable option for cervical cancer screening in female sex workers?. Cancer Nurs. 2018 Jan/Feb;41(1):45-52 |
| Wong EL, Chan PK, Chor JS, Cheung AW, Huang F, Wong SY. Evaluation of the impact of human papillomavirus DNA self-sampling on the uptake of cervical cancer screening. Cancer Nurs. 2016;39(1):E1. |
| Gao K, Eurasian M, Zhang J, Wei Y, Zheng Q, Ye H, Li L. Can genomic amplification of human telomerase gene and C-MYC in liquid-based cytological specimens be used as a method for opportunistic cervical cancer screening?. Gynecol Obstet Invest. 2015;80(3):153. |
| Liu L, Chen YM, Zhang QY, Li CZ. Roles of high-risk human papilloma virus (HR-HPV) E6/E7mRNA in triaging HPV16/18 cases. Clin Exp Obstet Gynecol. 2017;44(5):740. |
| Excluded for Study Design |
|---|
| Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. Primary cervical cancer screening with human papillomavirus: End of study results from the ATHENA study using HPV as the first-line screening test. Obstet Gynecol Surv. 2015;70(5):321. |
| Excluded for Populations |
|---|
| Sewali B, Okuyemi KS, Askhir A, Belinson J, Vogel RI, Joseph A, Ghebre RG. Cervical cancer screening with clinic-based Pap test versus home HPV test among Somali immigrant women in Minnesota: A pilot randomized controlled trial. Cancer Med. 2015;4(4):620. |
| Gustinucci D, Giorgi RossiP, Cesarini E, Broccolini M, Bulletti S, Carlani A, D’Angelo V, D’Amico MR, Di DatoE, Galeazzi P, Malaspina M, Martinelli N, Spita N, Tintori B, Giaimo MD, Passamonti B. Use of Cytology, E6/E7 mRNA, and p16INK4a-Ki-67 to define the management of human papillomavirus (HPV)-positive women in cervical cancer screening. Am J Clin Pathol. 2016;145(1):35. |
| Tewari D, Novak-Weekley S, Hong C, Aslam S, Behrens CM. Performance of the Cobas HPV test for the triage of atypical squamous cells of undetermined significance cytology in cervical specimens collected in SurePath. Am J Clin Pathol. Am J Clin Pathol. 2017 Nov 2;148(5):450-457. |
| Zhou H, Mody RR, Luna E, Armylagos D, Xu J, Schwartz MR, Mody DR, Ge Y. Clinical performance of the Food and Drug Administration-Approved high-risk HPV test for the detection of high-grade cervicovaginal lesions. Cancer Cytopathol.. 2016;124(5):317. |
| Heard I, Cuschieri K, Geraets DT, Quint W, Arbyn M. Clinical and analytical performance of the PapilloCheck HPV-Screening assay using the VALGENT framework. J Clin Virol. 2016 Aug;81:6-11. |
| Cuzick J, Myers O, Lee J-H, Shi Y, Gage JC, Hunt WC, Robertson M, Wheeler CM. Outcomes in women with cytology showing atypical squamous cells of undetermined significance with vs without human papillomavirus testing. JAMA Oncology. 2017;3(10):1327. |
| Comes MD, Oncins R, Clemente E, Aragon MA, Cortes A, Valles V, Guardia L, Millanes P. Prevalence of human papillomavirus and genotype distribution in women undergoing cervical cancer screening in the area of Barbastro, Spain. Revista Espanola de Patologia. 2016;49(4):208. |
| Dijkstra MG, van ZummerenM, Rozendaal L, Van Kemenade FJ, Helmerhorst TJ, Snijders PJ, Meijer CJ, Berkhof J. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands. BMJ 2016;355:i4924 |
| Leinonen MK, Schee K, Jonassen CM, Lie AK, Nystrand CF, Rangberg A, Furre IE, Johansson MJ, Trope A, Sjoborg KD, Castle PE, Nygard M. Safety and acceptability of human papillomavirus testing of self-collected specimens: A methodologic study of the impact of collection devices and HPV assays on sensitivity for cervical cancer and high-grade lesions. J Clin Virol. J Clin Virol. 2018 Feb - Mar;99-100:22-30. |
| Bhatia R, Serrano I, Wennington H, Graham C, Cubie H, Boland E, Fu G, Cuschieri K. An evaluation of a novel single tube method for extended genotyping of Human Papillomavirus. J Clin Microbiol. 2018 Mar; 56(3): e01687-17. |
| Igidbashian S, Boveri S, Bottari F, Vidal UrbinatiA, Preti E, Casadio C, Landoni F, Sideri M, Sandri MT. Prevalence and risk factors of human papillomavirus infection in 18-year-old women: baseline report of a prospective study on human papillomavirus vaccine. J Low Genit Tract Dis. 2017 Jan;21(1):4-8. |
| Isidean SD, Mayrand MH, Ramanakumar AV, Rodrigues I, Ferenczy A, Ratnam S, Coutlee F, Franco EL. Comparison of triage strategies for hpv positive women: Canadian cervical cancer screening trial results. Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):923-929. |
| Excluded for Interventions |
|---|
| Flannelly GM, Mooney MT, Greehy GM, Keogh EB, McNally SA, Fitzpatrick PE. Establishment of a national cervical screening programme in Ireland, CervicalCheck: the first 6 years. Eur J Cancer Prev. 2018 Mar;27(2):158-163. |
| Tracht J, Wrenn A, Eltoum IE. Primary HPV testing verification: A retrospective ad-hoc analysis of screening algorithms on women doubly tested for cytology and HPV. Diagn Cytopathol. 2017 Jul;45(7):580-586. |
| MacLaughlin KL, Kessler ME, Komandur ElayavilliR, Hickey BC, Scheitel MR, Wagholikar KB, Liu H, Kremers WK, Chaudhry R. Impact of patient reminders on papanicolaou test completion for high-risk patients identified by a clinical decision support system. J Womens Health (Larchmt). 2018 May;27(5):569-574. |
| Silver MI, Schiffman M, Fetterman B, Poitras NE, Gage JC, Wentzensen N, Lorey T, Kinney WK, Castle PE. The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen. Cancer. 2016;122(23):3682. |
| Del MistroA, Frayle H, Ferro A, Fantin G, Altobelli E, Giorgi RossiP. Efficacy of self-sampling in promoting participation to cervical cancer screening also in subsequent round. Prev Med Rep. 2017;5:166-168. |
| Excluded for Comparators |
|---|
| Lim AW, Hollingworth A, Kalwij S, Curran G, Sasieni P. Offering self-sampling to cervical screening non-attenders in primary care. J Med Screen. 2017;24(1):43. |
| Passamonti B, Gustinucci D, Giorgi RossiP, Cesarini E, Bulletti S, Carlani A, Martinelli N, Broccolini M, D’Angelo V, D’Amico MR, Di DatoE, Galeazzi P, Malaspina M, Spita N, Tintori B, Giaimo MD. Cervical human papilloma virus (HPV) DNA primary screening test: Results of a population-based screening programme in central Italy. J Med Screen. J Med Screen. 2017 Sep;24(3):153-162. |
| Passamonti B, Gustinucci D, Giorgi RossiP, Cesarini E, Bulletti S, Carlani A, Martinelli N, Broccolini M, D’Angelo V, D’Amico MR, Di DatoE, Galeazzi P, Malaspina M, Spita N, Tintori B, Giaimo MD. Cervical human papilloma virus (HPV) DNA primary screening test: Results of a population-based screening programme in central Italy. J Med Screen. 2017;24(3):153. |
| Ejegod D, Bottari F, Pedersen H, Sandri MT, Bonde J. The BD Onclarity HPV assay on samples collected in surepath medium meets the international guidelines for human papillomavirus test requirements for cervical screening. J Clin Microbiol. 2016;54(9):2267. |
| Cuzick J, Cuschieri K, Denton K, Hopkins M, Thorat MA, Wright C, Cubie H, Moore C, Kleeman M, Austin J, shdown-Barr L, Hunt K, Cadman L. Performance of the Xpert HPV assay in women attending for cervical screening. Papillomavirus Research. 2015;1:32-37. |
| Monsonego J, Cox JT, Behrens C, Sandri M, Franco EL, Yap PS, Huh W. Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: Data from the ATHENA trial. Gynecol Oncol. 2015;137(1):47. |
| Lam JUH, Elfstrom KM, Ejegod DM, Pedersen H, Rygaard C, Rebolj M, Lynge E, Juul KE, Kjaer SK, Dillner J, Bonde J. High-grade cervical intraepithelial neoplasia in human papillomavirus self-sampling of screening non-attenders. Br J Cancer. Br J Cancer. 2018 Jan;118(1):138-144 |
| Zorzi M, Frayle H, Rizzi M, Fedato C, Rugge M, Penon MG, Bertazzo A, Callegaro S, Campagnolo M, Ortu F, Del MistroA, Veneto HPV-screening Working Group. A 3-year interval is too short for re-screening HPV negative women: a population-based cohort study. BJOG. BJOG. 2017 Sep;124(10):1585-1593. |
| Uijterwaal MH, Polman NJ, Van Kemenade FJ, Van Den HaselkampS, Witte BI, Rijkaart D, Berkhof J, Snijders PJ, Meijer CJ. Five-year cervical (pre)cancer risk of women screened by hpv and cytology testing. Cancer Prev Res (Phila Pa). 2015;8(6):502. |
| Excluded for Outcomes |
|---|
| Coldman AJ, Gondara L, Smith LW, van NiekerkD, Ceballos K, Krajden M, Cook D, Quinlan DJ, Lee M, Stuart GC, Peacock S, Martin RE, Gentile L, Franco EL, Ogilvie GS. Disease detection and resource use in the safety and control arms of the HPV FOCAL cervical cancer screening trial. Br J Cancer. 2016;115(12):1487. |
| Cook DA, Mei W, Smith LW, van Niekerk DJ, Ceballos K, Franco EL, Coldman AJ, Ogilvie GS, Krajden M. Comparison of the Roche cobas 4800 and Digene Hybrid Capture 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial. BMC Cancer. 2015;15:968. |
| Stanczuk G, Baxter G, Currie H, Lawrence J, Cuschieri K, Wilson A, Arbyn M. Clinical validation of hrHPV testing on vaginal and urine self-samples in primary cervical screening (cross-sectional results from the Papillomavirus Dumfries and Galloway-PaVDaG study). BMJ Open. 2016;6(4):e010660, 2016. |
| Rebolj M, Bonde J, Preisler S, Ejegod D, Rygaard C, Lynge E. Human papillomavirus assays and cytology in primary cervical screening of women aged 30 years and above. PLoS One. 2016 Jan 20;11(1):e0147326. |
| Castle PE, Aslam S, Behrens C. Cervical precancer and cancer risk by human papillomavirus status and cytologic interpretation: Implications for risk-based management. Cancer Epidemiol Biomarkers Prevent. 2016;25(12):1595. |
| Isidean SD, Mayrand MH, Ramanakumar AV, Gilbert L, Reid SL, Rodrigues I, Ferenczy A, Ratnam S, Coutlee F, Franco EL, CCCaST Study Group. Human papillomavirus testing versus cytology in primary cervical cancer screening: End-of-study and extended follow-up results from the Canadian cervical cancer screening trial. Int J Cancer. 2016;139(11):2456. |
